Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Benzinga Insights 8 months ago
Analyst Ratings
In the last three months, 5 analysts have published ratings on Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 0 | 0 | 2 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 2 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $22.8, a high estimate of $38.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 4.83% from the previous average price target of $21.75.
Decoding Analyst Ratings: A Detailed Look
The standing of Sarepta Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $38.00 | $45.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Maintains | Sell | $5.00 | $5.00 |
| Yun Zhong | Wedbush | Raises | Outperform | $34.00 | $32.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Maintains | Sell | $5.00 | $5.00 |
| Yun Zhong | Wedbush | Announces | Outperform | $32.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sarepta Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Sarepta Therapeutics's Background
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Breaking Down Sarepta Therapeutics's Financial Performance
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Sarepta Therapeutics's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -14.52% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sarepta Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -45.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sarepta Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.44%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Sarepta Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -5.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.95, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.